Article
Top Institute for Value-Based Medicine® Content in 2022
Author(s):
Across several Institute for Value-Based Medicine® (IVBM) events held in 2022, the most-viewed content from these events cover a variety of topics in oncology care.
The top 5 most-viewed content from various Institute for Value-Based Medicine® (IVBM) events hosted by The American Journal of Managed Care® (AJMC®) this year included interviews on disparities in immunotherapy delivery and biosimilar implementation, as well as recaps focusing on conversations around value-based cancer care.
Here is the most-viewed content from our IVBM events in 2022.
5. Multidisciplinary Care as the Catalyst for Innovation in Oncology
This recap focuses on the IVBM event in Atlanta, Georgia, held in partnership with Emory Winship Cancer Institute and chaired by Ryan Haumschild, PharmD, MS, MBA, director of pharmacy services, Emory Healthcare and Emory Winship Cancer Institute.
At this IVBM event, speakers covered topics driving innovation in multidisciplinary cancer care, including the use of biosimilars, comprehensive genomic profiling, and precision medicine. Panelists also discussed also addressed disparities in prostate cancer care treatment and preventive strategies to address the rising threat of human papillomavirus-related oropharynx cancer.
4. Dr Amila Patel Highlights Findings on Disparities in Immunotherapy Delivery
In this interview at the IVBM event in Austin, Texas, in partnership with Texas Oncology, AJMC® spoke with Amila Patel, PharmD, chief clinical officer of Navigating Cancer, about data presented at the American Society of Clinical Oncology annual meeting. The study, which used data from Navigating Cancer, found that non-White patients are less likely to receive immunotherapy for head and neck cancer. Here, Patel elaborates on changes that can be made in how immunotherapy is delivered.
3. Practices Have to Grapple With the Logistics of Insurers’ Preferred Biosimilars: Dr Lalan Wilfong
For AJMC®'s IVBM event in partnership with Texas Oncology, Lalan Wilfong, MD, vice president of payer relations & practice transformation at The US Oncology Network, explained that commercial payers all have their own preferred biosimilar, which makes it challenging for practices. However, it is important to note they have been engaged with the shift to biosimilars, he said.
2. Dr Timothy Murphy Discusses Successfully Implementing Biosimilars Into Community Cancer Practice
AJMC® sat down with Timothy Murphy, MD, medical oncologist/hematologist with Rocky Mountain Cancer Centers (RMCC) at the IVBM event in Greenwood Village, Colorado, in partnership with RMCC. According to Murphy, having a plan in place to educate providers and the pharmacy team has contributed to RMCC’s success with rapidly implementing biosimilars,
1. Shifting Landscape of Care Delivery Is Impacting Value-Based Cancer Care
This recap focuses on AJMC®'s IVBM event in partnership with Texas Oncology. Debra Patt, MD, PhD, MBA, executive vice president of policy and strategic initiatives at Texas Oncology, and chair of the IVBM event, explained that discussions of value in cancer care should also include the protection of community oncology, which allows patients to receive care where they live. This IVBM event covered a range of topics related to value-based cancer care, including oral oncolytics, electronic patient-reported outcomes, and state and federal policy.
